100 related articles for article (PubMed ID: 27095144)
1. FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center.
Yılmaz Bengoa Ş; Ataseven E; Kızmazoğlu D; Demir Yenigürbüz F; Erdem M; Ören H
Turk J Haematol; 2017 Mar; 34(1):46-51. PubMed ID: 27095144
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
3. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
[TBL] [Abstract][Full Text] [Related]
4. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
[TBL] [Abstract][Full Text] [Related]
5. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
7. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
8. [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Qian SX; Li JY; Wu HX; Zhang R; Hong M; Xu W; Qiu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):464-7. PubMed ID: 19379589
[TBL] [Abstract][Full Text] [Related]
9. FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias.
Farooq MU; Mushtaq F; Farooq A; Khan DH; Mir MA
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1191-1193. PubMed ID: 30887181
[TBL] [Abstract][Full Text] [Related]
10. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
[TBL] [Abstract][Full Text] [Related]
11. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
12. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
[TBL] [Abstract][Full Text] [Related]
14. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
15. FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission.
Deane M; Koh M; Foroni L; Galactowicz G; Hoffbrand AV; Lawler M; Secker-Walker L; Prentice HG
Bone Marrow Transplant; 1998 Dec; 22(12):1137-43. PubMed ID: 9894715
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients.
Alwan AF; Matti BF; Naji AS; Jawad AM
Indian J Hematol Blood Transfus; 2014 Dec; 30(4):231-5. PubMed ID: 25435719
[TBL] [Abstract][Full Text] [Related]
17. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
[TBL] [Abstract][Full Text] [Related]
18. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
19. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
[TBL] [Abstract][Full Text] [Related]
20. FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia-Even in the Era of New Treatment Modalities Still a Significant Player.
Anžej Doma S; Sever M; Jakoš G; Podgornik H
J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]